解决转移性结肠直肠癌向治疗的挑战
Maria El Hage1, Zhaoran Su1, Michael Linnebacher1
1Molecular Oncology and Immunotherapy, Clinic of General Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Cancers
|April 14, 2025
概括
转移性结直肠癌 (mCRC) 的向治疗面临着由初级和二级抗性机制带来的挑战. 克服这些需要组合疗法和基因组生物标志物,以优化治疗结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 转移性结直肠癌 (mCRC) 的治疗依赖于向治疗.
- 已批准的疗法包括抗血管原剂,EGFR,BRAFV600E,HER2抑制剂和免疫检查点.
- 对这些疗法的耐药性是一个重大的临床挑战.
研究的目的:
- 审查已批准的针对mCRC的向治疗方法.
- 讨论一级和二级抵抗机制.
- 探索克服耐药性和改善治疗结果的策略.
主要方法:
- 对mCRC的向治疗方法的文献综述.
- 对抗性机制的分析,包括瘤异质性和遗传变化.
- 讨论组合治疗策略和基因组生物标志物集成.
主要成果:
- 对于mCRC,有多种向治疗方法可供选择.
- 主要的抵抗机制包括瘤异质性.
- 二次性耐药性包括驱动性瘤基因的改变,旁路信号传递,共主导性瘤基因,谱系可塑性和上皮-介质酶过渡.
- 组合疗法可以增加毒性.
- 成本和可访问性是重要的障碍.
结论:
- 针对mCRC的向治疗是复杂的,因为抵抗机制.
- 组合疗法和基因组生物标志物 (测序,液体活检) 是有希望的策略.
- 需要进一步的研究来优化针对性治疗的使用和解决可访问性问题.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


